Development of monoclonal antibodies for the treatment of colorectal cancer
- 1 June 2008
- journal article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 65 (11_Supplem), S3-S7
- https://doi.org/10.2146/ajhp080100
Abstract
Purpose. The timeline for development, types, mechanisms of action, characteristics, and nomenclature of monoclonal antibodies used in cancer treatment; characteristics of the ideal target antigen; and currently available monoclonal antibody products for the treatment of colorectal cancer that target epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) are described.Keywords
This publication has 12 references indexed in Scilit:
- Panitumumab the first fully human monoclonal antibody: from the bench to the clinicAnti-Cancer Drugs, 2007
- EGFR-Targeting Monoclonal Antibodies in Head and Neck CancerCurrent Cancer Drug Targets, 2006
- Heregulins Implicated in Cellular Functions Other Than Receptor ActivationMolecular Cancer Research, 2006
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cellsSeminars in Oncology, 2003
- Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiationSeminars in Oncology, 2002
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCritical Reviews in Oncology/Hematology, 2001
- The EGF Receptor System as a Target for Antitumor TherapyCancer Investigation, 1991
- Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusionEuropean Journal of Immunology, 1976